1. Home
  2. SNTI vs SCNX Comparison

SNTI vs SCNX Comparison

Compare SNTI & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$1.04

Market Cap

53.6M

Sector

Health Care

ML Signal

HOLD

Logo Scienture Holdings Inc.

SCNX

Scienture Holdings Inc.

HOLD

Current Price

$0.50

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTI
SCNX
Founded
2016
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Pharmaceuticals
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.6M
24.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SNTI
SCNX
Price
$1.04
$0.50
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
352.8K
1.7M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$653,391.00
Revenue This Year
N/A
N/A
Revenue Next Year
$150.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
207.88
52 Week Low
$1.02
$0.46
52 Week High
$5.10
$4.50

Technical Indicators

Market Signals
Indicator
SNTI
SCNX
Relative Strength Index (RSI) 35.43 40.46
Support Level $1.04 $0.49
Resistance Level $1.09 $0.60
Average True Range (ATR) 0.06 0.04
MACD 0.02 0.00
Stochastic Oscillator 12.56 5.39

Price Performance

Historical Comparison
SNTI
SCNX

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About SCNX Scienture Holdings Inc.

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Share on Social Networks: